View Item 

Show simple item record

Drug Dosing During Continuous Renal Replacement Therapy
dc.contributor.authorChurchwell, Mariann D.en_US
dc.contributor.authorMueller, Bruce A.en_US
dc.date.accessioned2010-06-01T19:40:59Z
dc.date.available2010-06-01T19:40:59Z
dc.date.issued2009-03en_US
dc.identifier.citationChurchwell, Mariann D.; Mueller, Bruce A. (2009). "Drug Dosing During Continuous Renal Replacement Therapy." Seminars in Dialysis 22(2): 185-188. <http://hdl.handle.net/2027.42/72817>en_US
dc.identifier.issn0894-0959en_US
dc.identifier.issn1525-139Xen_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72817
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19426426&dopt=citationen_US
dc.format.extent100457 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights© 2009 Wiley Periodicals, Inc.en_US
dc.titleDrug Dosing During Continuous Renal Replacement Therapyen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum† Department of Clinical, Social and Administrative Sciences, University of Michigan College of Pharmacy, Ann Arbor, Michiganen_US
dc.contributor.affiliationother* Department of Pharmacy Practice, University of Toledo, College of Pharmacy, Toledo, Ohioen_US
dc.identifier.pmid19426426en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72817/1/j.1525-139X.2008.00541.x.pdf
dc.identifier.doi10.1111/j.1525-139X.2008.00541.xen_US
dc.identifier.sourceSeminars in Dialysisen_US
dc.identifier.citedreferenceJoy MS, Matzke GR, Armstrong DK, Marx MA, Zarowitz BJ: A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother 32: 362 – 375, 1998en_US
dc.identifier.citedreferenceVilay AM, Churchwell MD, Mueller BA: Drug metabolism and clearance in acute kidney injury. Crit Care 12: 235 ( doi: ), 2008en_US
dc.identifier.citedreferenceNolin TD, Naud J, Leblond FA, Pichette V: Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 83: 898 – 903, 2008en_US
dc.identifier.citedreferenceMueller BA, Scarim SK, Macias WL: Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Am J Kidney Dis 21: 172 – 179, 1993en_US
dc.identifier.citedreferenceNolin TD, Appiah K, Kendrick SA, Le P, McMonagle E, Himmelfarb J: Hemodialysis acutely improves hepatic CYP3A4 metabolic activity. J Am Soc Nephrol 17: 2363 – 2367, 2006en_US
dc.identifier.citedreferenceMueller BA, Pasko DA, Sowinski KM: Higher renal replacement therapy dose delivery influences on drug therapy. Artif Organs 27: 808 – 814, 2003en_US
dc.identifier.citedreferenceJoy MS, Matzke GR, Frye RF, Palevsky PM: Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am J Kidney Dis 31: 1019 – 1027, 1998en_US
dc.identifier.citedreferenceChurchwell MD, Pasko DA, Mueller BA: Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif 24: 548 – 554, 2006en_US
dc.identifier.citedreferenceUchino S, Cole L, Morimatsu H, Goldsmith D, Bellomo R: Clearance of vancomycin during high-volume haemofiltration: impact of pre-dilution. Intensive Care Med 28: 1664 – 1667, 2002en_US
dc.identifier.citedreferenceBrunet S, Leblanc M, Geadah D, Parent D, Courteau S, Cardinal J: Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis 34: 486 – 492, 1999en_US
dc.identifier.citedreferencePasko DA, Churchwell MD, Mueller BA: Duration of Continuous Venovenous Hemodialysis and Dialysate Flow Rate on Solute Saturation Coefficient (abstract). European Society of Clinical Pharmacy Conference, 2004, Paris, Franceen_US
dc.identifier.citedreferencePasko DA, Churchwell MD, Mueller BA: Duration of Continuous Hemofiltration and Ultrafiltration Rate Influence on Sieving Coefficients (abstract). European Society of Clinical Pharmacy Conference, 2004, Paris, Franceen_US
dc.identifier.citedreferenceZaske DE, Cipole RJ, Rotschafer JC, Solem LD, Mosier NR, Strate RG: Gentamicin pharmacokinetics in 1640 patients: methods for control of serum concentrations. Antimicrob Agents Chemother 21: 407 – 411, 1982en_US
dc.identifier.citedreferenceNicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R: Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother 39: 650 – 655, 1995en_US
dc.identifier.citedreferenceBuijk SE, Mouton JW, Gyssens IC, Verbrugh HA, Bruining HA: Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 28: 936 – 942, 2002en_US
dc.identifier.citedreferenceDvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H: Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother 48: 2799 – 2807, 2004en_US
dc.identifier.citedreferenceCubist Pharmaceuticals, Inc. Cubicin (Daptomycin for Injection) Package Insert. Lexington MA: Cubist Pharmaceuticals, Inc., 2007.en_US
dc.identifier.citedreferenceVilay AM, Grio MC, DePestel DD, Sowinski KM, Gao L, Salama NN, Mueller BA: Daptomycin Pharmacokinetics in Patients Treated With Continuous Venovenous Hemodialysis (CVVHD) ( abstract ). American Society of Nephrology Renal Week, 2008, Philadelphia, PAen_US
dc.identifier.citedreferenceBush LM, Boscia JA, Wendeler M, Pitsakis PG, Kaye D: In vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 33: 1198 – 1200, 1989en_US
dc.identifier.citedreferenceHanberger H, Nilsson LE, Maller R, Isaksson B: Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob Agents Chemother 35: 1710 – 1716, 1991en_US
dc.identifier.citedreferenceAronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, Pasko DA, Smoyer WE: Drug Prescribing in Renal Failure Dosing Guidelines for Adults and Children, 5th edn. Philadelphia: American College of Physicians, 2007en_US
dc.identifier.citedreferenceMicromedex: Micromedex® Healthcare Series ( electronic version ). Greenwood Village, CO: Thomson Micromedex. Available at http://www.thomsonhc.com, accessed August 26, 2008en_US
dc.identifier.citedreferenceVidal L, Shavit M, Fraser A, Paul M, Leibovici L: Systematic comparison of four sources of drug information regarding adjustment of dose for renal function. BMJ 331: 263 ( doi :, published May 19, 2005), 2005en_US
dc.identifier.citedreferenceAronoff GR: Dose adjustment in renal impairment: response from drug prescribing in renal failure. BMJ 30: 331, 2005en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1525-139X.2008.00541.x.pdf
Size:
98.10KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.